Glutamic Acid News and Research

RSS
Changes in endocannabinoid system may have important implications for psychiatric disorders

Changes in endocannabinoid system may have important implications for psychiatric disorders

TrialNet presents Diamyd Phase II study results on type 1 diabetes at ADA 2011

TrialNet presents Diamyd Phase II study results on type 1 diabetes at ADA 2011

Diamyd Medical to terminate US DiaPrevent Phase III study for type 1 diabetes

Diamyd Medical to terminate US DiaPrevent Phase III study for type 1 diabetes

Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease

Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease

Diamyd European Phase III study in diabetes does not meet primary endpoint

Diamyd European Phase III study in diabetes does not meet primary endpoint

Neurologix presents NLX-P101 Phase 2 trial in Parkinson's disease at 10th INS World Congress

Neurologix presents NLX-P101 Phase 2 trial in Parkinson's disease at 10th INS World Congress

Diamyd Medical announces European Phase III study results in type 1 diabetes

Diamyd Medical announces European Phase III study results in type 1 diabetes

The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD

The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD

Results from first successful phase 2 trial of gene therapy for Parkinson's or any neurologic disorder

Results from first successful phase 2 trial of gene therapy for Parkinson's or any neurologic disorder

Neurologix third quarter net loss decreases to $2.3 million

Neurologix third quarter net loss decreases to $2.3 million

Neurologix holds license for gene therapy to treat severe depression

Neurologix holds license for gene therapy to treat severe depression

Researchers suggest gene therapy may treat patients with major depression

Researchers suggest gene therapy may treat patients with major depression

Neurologix second-quarter net loss increases to $4.5 million

Neurologix second-quarter net loss increases to $4.5 million

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

US PTO grants new allowances to intellectual property covering Neurologix' GAD based delivery systems

US PTO grants new allowances to intellectual property covering Neurologix' GAD based delivery systems

USPTO issues new patent for Advaxis' intellectual property portfolio

USPTO issues new patent for Advaxis' intellectual property portfolio

Researchers identify new biological pathway of H1N1 transmission to human population

Researchers identify new biological pathway of H1N1 transmission to human population

Bird influenza viruses have a variety of strategies to cross the species barrier

Bird influenza viruses have a variety of strategies to cross the species barrier

University of Michigan to develop novel therapy for neuropathic pain

University of Michigan to develop novel therapy for neuropathic pain

NCKU transfers microalgal docosahexaenoic acid production technology to Vedan Biotechnology

NCKU transfers microalgal docosahexaenoic acid production technology to Vedan Biotechnology